| P/E (FY) | — | Sales (TTM) | $55.6M |
| Earnings (TTM) | -$158.1M | ROE | −217.94% |
| Net Margin | −297.07% | ROIC | −242.72% |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | −15.66% |
| Market Cap | $2.39B | Trading Days | 5292 |
| 52W High | 109.00 |
| 52W Low | 21.02 |
| % Off High | −35.07% |
| YTD | 67.38% | 1Y | 199.24% |
| 3Y | 770.02% | 5Y | −70.82% |
| 10Y | −70.55% | Since incept. (ann.) | −6.26% |
Non Cash Royalty Revenue Related To Sale Of Future Royalties 50% · Non Cash Royalties 50% · License Collaboration And Other Revenue 0%
| Ann. Volatility (1Y) | 90.64% | Ann. Volatility (3Y) | 140.11% |
| Sharpe (1Y) | 1.64 | Sharpe (3Y) | 1.04 |
| Max Drawdown (1Y) | −46.54% | Max Drawdown (3Y) | −73.22% |
| Beta (3Y, vs SPY) | 1.21 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| VERA | Vera Therapeutics, Inc. | $2.39B | — |
| PBH | Prestige Consumer Healthcare Inc. | $2.45B | 13.2 |
| NUVB | Nuvation Bio Inc. | $2.33B | — |
| ALMS | ALUMIS INC. | $2.30B | — |
| NRIX | Nurix Therapeutics, Inc. | $2.51B | — |
| KLRA | Kailera Therapeutics, Inc. | $2.26B | — |
| RARE | Ultragenyx Pharmaceutical Inc. | $2.56B | — |
| MLYS | Mineralys Therapeutics, Inc. | $2.22B | — |
| GRTX | Galera Therapeutics, Inc. | $2.61B | 25.4 |
| TRVI | Trevi Therapeutics, Inc. | $2.62B | — |
| IMNM | Immunome Inc. | $2.63B |
| AMLX | Amylyx Pharmaceuticals, Inc. | $2.17B | — |
